Spent a few hours on Protalix Biotherapeutics (PLX) yesterday reading the last 10-Q going over the sales agreements that they have. The $3.35 price range is where I plan to buy in. The current business agreement they have on sales has them net neutral through 2018. Meaning their unique drug delivery platform and all other research phase projects are free. Within the next three months, 2-3 major research result announcements are expected.
Current Zack's price target is $3.40 and "hold" rating recommended. I expect an increase of $1.7 million in revenues offset by an expense of $1.7 million towards Pfizer agreement. Revenues should increase as PLX has recently been approved for administration in Australia and Canada. Additionally, I feel this treatment plays into the Obamacare cost efficiency angle as it is a biobetter drug replacement with a price tag of $140,000 versus the standard $200,000 per year.
This is an Israeli based company, and there is a war going on over there right now.
The Phase Studies
The 28 day Phase 2a trial is in progress and it is a game changer folks. On positive results, PLX could get immediate pass through license from FDA to sell it provisionally. Oral Eleyseo tablets validate the ProCellEx drug development platform - licenseable technology. Oral Eleyseo is a whole new market place, no more painful injections. Grab your medicine and take it in the comfort of your own home. New President of the Board of Directors was a former president of Teva Pharmaceuticals for a five year period. Teva is a $50 billion dollar company. After he left there, he went to another company that was monetized in a sale to the Chinese government. This guy is serious folks.
The Eleyseo deal with Brazil will generate roughly $5.2 million for the next seven quarters. $1.7 million payment to Pfizer (60%) towards partnership agreement. Nice steady pay rate of ~$3.5 million as shown in first quarter. Cap at $12,255,000 million instead of $18 million. Running a rough calculation on the contracts and current financial developments from Pfizer Agreement around the world (with no new customers). PLX will be able to fund all business responsibilities (Research and corporate) for the next four years with cash on hand and sales from this one drug. They will have enough money at the end to pay off the $67 million dollar 4.5% interest rate they took out.
Obamacare and Eleyseo, Eleyseo is roughly $60,000 dollars a year cheaper than competitors. One of those competitors was Shire, and if that name sounds familiar it's because AbbVie just came to a buyout agreement with them. I believe 36 month safety results will lead to the license of pediatric patients.
You get all the drugs in the pipeline, Eleyseo deal, and the drug platform that can be monetized for the price of a share with no dilution coming as I project it.
Disclosure: I am a private investor with no ties or affiliations to any organization or corporation. I am investing my own money that I hopefully will be able to purchase a home for my family with. I've spent probably ten hours researching the various aspects of this company and am offering my personal opinion on the future prospects of this organization. I am currently long 10,000 shares and hold options in the $3-5 dollar range.
The Eleyseo deal with Brazil will generate roughly $5.2 million for the next seven quarters. $1.7 million payment to Pfizer (60%) towards partnership agreement. Nice steady pay rate of ~$3.5 million as shown in first quarter. Cap at $12,255,000 million instead of $18 million. Running a rough calculation on the contracts and current financial developments from Pfizer Agreement around the world (with no new customers). PLX will be able to fund all business responsibilities (Research and corporate) for the next four years with cash on hand and sales from this one drug. They will have enough money at the end to pay off the $67 million dollar 4.5% interest rate they took out.
Obamacare and Eleyseo, Eleyseo is roughly $60,000 dollars a year cheaper than competitors. One of those competitors was Shire, and if that name sounds familiar it's because AbbVie just came to a buyout agreement with them. I believe 36 month safety results will lead to the license of pediatric patients.
You get all the drugs in the pipeline, Eleyseo deal, and the drug platform that can be monetized for the price of a share with no dilution coming as I project it.
Disclosure: I am a private investor with no ties or affiliations to any organization or corporation. I am investing my own money that I hopefully will be able to purchase a home for my family with. I've spent probably ten hours researching the various aspects of this company and am offering my personal opinion on the future prospects of this organization. I am currently long 10,000 shares and hold options in the $3-5 dollar range.
